title: Evolution of uncontrolled proliferation and the angiogenic switch in cancer.
abstract: The major goal of evolutionary oncology is to explain how malignant traits evolve to become cancer ``hallmarks." One such hallmark---the angiogenic switch---is difficult to explain for the same reason altruism is difficult to explain. An angiogenic clone is vulnerable to ``cheater" lineages that shunt energy from angiogenesis to proliferation, allowing the cheater to outcompete cooperative phenotypes in the environment built by the cooperators. Here we show that cell- or clone-level selection is sufficient to explain the angiogenic switch, but not because of direct selection on angiogenesis factor secretion---angiogenic potential evolves only as a pleiotropic afterthought. We study a multiscale mathematical model that includes an energy management system in an evolving angiogenic tumor. The energy management model makes the counterintuitive prediction that ATP concentration in resting cells increases with increasing ATP hydrolysis, as seen in other theoretical and empirical studies. As a result, increasing ATP hydrolysis for angiogenesis can increase proliferative potential, which is the trait directly under selection. Intriguingly, this energy dynamic allows an evolutionary stable angiogenesis strategy, but this strategy is an evolutionary repeller, leading to runaway selection for extreme vascular hypo- or hyperplasia. The former case yields a tumor-on-a-tumor, or hypertumor, as predicted in other studies, and the latter case may explain vascular hyperplasia evident in certain tumor types.
authors: Department of Life Sciences, Scottsdale Community College, 9000 E. Chaparral Rd., Scottsdale, AZ 85256, United States. john.nagy@scottsdalecc.edu
authors: John D
authors: JD
authors: Nagy
authors: Dieter
authors: D
authors: Armbruster
mesh_terms: D042501:Angiogenic Proteins / Q000378:metabolism*; D000818:Animals; D049109:Cell Proliferation; D003198:Computer Simulation; D019143:Evolution, Molecular; D005812:Genes, Switch / Q000235:genetics*; D006801:Humans; D008954:Models, Biological; D009369:Neoplasms / Q000150:complications / Q000473:pathology* / Q000503:physiopathology*; D009389:Neovascularization, Pathologic / Q000150:complications / Q000473:pathology* / Q000503:physiopathology*
chemical_list: D042501:Angiogenic Proteins